better than all the rest

Houston school recognized as among the top institutions in the nation

Rice University has again topped a list of the best schools in the country. Photo courtesy of Rice University

Houston's Rice University continues to burnish its reputation in higher education.

A ranking released May 5 by QS Quacquarelli Symonds, a British company that specializes in higher education data, puts Rice at No. 23 among the top colleges and universities in the U.S. It's the highest-rated Texas school on the list.

Harvard University appears at No. 1 in the ranking, followed by Stanford University; the Massachusetts Institute of Technology (MIT); the University of California, Berkeley; and the University of California, Los Angeles (UCLA).

Elsewhere in Texas:

  • The University of Texas at Austin ranks 29th.
  • Texas A&M University in College Station ranks 64th.
  • The University of Houston ranks 66th.
  • The University of Texas at Dallas ranks 83rd.

To come up with its ranking, QS Quacquarelli Symonds looked at five factors for more than 350 colleges and universities around the country: employability, learning experience, diversity and internationalization, and research.

Here's how Rice fares in each of those categories:

  • Employability, No. 42.
  • Learning experience, No. 7.
  • Diversity and internationalization, tied for No. 32.
  • Research, No. 33.

Jack Moran, a spokesman for QS Quacquarelli Symonds, says that although the rankings "continue to command record levels of interest, we know that the American higher education sector is wrestling with questions that do not fall within the scope of our … rankings — questions of equity, access, representation, and social justice."

"The QS USA University Rankings have been carefully crafted to shine some independent light on which institutions are doing most to foster the essential relationship between education and social change," Moran adds.

More students soon will be able to take advantage of the top-rated education offered by Rice. In March, the private university announced it would expand the number of undergraduates by 20 percent by the fall of 2025. This would raise undergraduate enrollment to 4,800 and total enrollment to about 9,000.

"Rice's extraordinary applicant pool has grown dramatically despite the challenges posed by the pandemic," President David Leebron says in a news release.

Rice says the number of student applications has climbed 75 percent over the past four years. In 2020, the university received roughly 28 applications for every available slot. For the fall of 2021, almost 30,000 applicants flooded Rice, up 26 percent from the previous year.

Leebron says Rice's previous expansion of enrollment "greatly increased our national and international student applications, enrollment, and visibility. We also dramatically increased diversity on our campus, and we were able to extend the benefits of a Rice education to many more students."

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted